The quantitative objective is to identify the effectiveness of intravenous iron administration on the correction of iron deficiency anaemia in the perioperative setting.
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Background
Most countries from around the world are facing significant demographic changes over the next two decades. 1 These changes come as the result of a dramatic increase in the older population and a decrease of the young due to an ongoing decline in birth rates in the western world. More complex surgery in the elderly in addition to many serious medical conditions requiring transfusion will consequently lead to an increase in demand for blood products. The shrinking pool of donors will compound the problem and demand threatens to outstrip supply. This looming shortfall has to be addressed urgently to guarantee the sustainability of the blood supply.
The transfusion of red blood cells (RBC) for the correction of anaemia is a widely accepted treatment modality and a common occurrence in the peri-operative period. In the USA 16 million units of blood are collected each year but only 20 % of all transfusions are given in haemorrhagic shock to the hemodynamically unstable patient and may be potentially lifesaving. 2 However most RBC are prescribed to stable patients according to empirical guidelines. According to available evidence many of these transfusion events can be considered inappropriate. Guidelines appear to be frequently ignored or underutilised and many clinicians revert to transfusion practices based on individual beliefs. 3 Despite an increasing body of evidence that peri-operative allogeneic transfusion contributes to worse outcomes, such as, increased lengths of stay (LOS), increased infection rates, increased occurrence of transfusion related lung injury (TRALI), transfusion related circulatory overload (TACO) and the number of deaths, this form of anaemia management continues. Many of these transfusion events could be avoided if more attention was spend on optimising pre-operative haemoglobin values and the patients iron status.
Iron deficiency anaemia (IDA) is a common condition. Age, socio-economic circumstances, poor nutrition, and physiological processes (for example pregnancy), with a substantial increase in iron demand, can result in anaemia. Many pathological states also commonly lead to severe iron depletion. These include inflammatory bowel disease, colo-rectal cancer and menorrhagia. In patients presenting for surgery iron deficiency (with or without anaemia), is found in up to 39% of non-cardiac surgical patients. 4 In certain subgroups of patient, for example colon and rectal surgery patients the occurrence of preoperative anaemia has been found to be as high as 47.5%. For all anaemic patients this results frequently in an increased number of cardiac complications, increased number of days in hospital, more allogeneic transfusion events and more deaths, A more recent publication confirmed the incidence and stated that even mild forms of anaemia increase 30 days mortality. 5 These findings imply that preoperative anaemia screening and correction should become an integral part of the preoperative assessment and management process.
In many countries transfusion related costs are not apparent and of no consequence to the physician or the patient. In some countries like Australia, these costs are not even of any consequences for the hospital. This situation does not provide a platform for initiatives to facilitate change and illustrates the need for reform.
Experts from around the world have designed comprehensive patient blood management (PBM) programs which provide effective approaches to optimise patient care. Patients from certain risk groups should be assessed ideally at least 4 weeks prior to particularly major surgery. 6 This would allow clinicians to interpret blood results with a window of opportunity to act. In addition, unless urgent, surgery should also be considered to be delayed, to investigate the cause of the anaemia. If not possible to undertake prior to surgery, the investigations have to be performed at a later stage.
With the common occurrence of iron deficiency anaemia, it appears to be one of the key aspects of PBM. Oral iron replacement can be effective but is in many instances poorly tolerated. There is increasing evidence that in select patient groups presenting for elective surgery, but also in urgent cases, a more contemporary approach with intravenous iron might benefit the patient and will result in improved outcomes and a reduction of RBC transfusion.
The economic benefits of preoperative anaemia correction are difficult to assess. Multiple transfusion cost assessments exist and differ between countries However, market forces in combination with additional testing for emerging new pathogens will lead to an increase in cost. Cost of transfusion and transfusion related morbidity has to be balanced against the cost of robust preoperative anaemia management. The Canadian ONTraC program placed a network of nurse transfusion coordinators in 23 hospitals. These hospitals accounted for 65% of allogeneic red blood cell transfusions. Most hospitals reduced their red cell consumption significantly allowing for estimated potential annual cost savings of 14.6 Million dollars.
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A preliminary search of the JIB library, Medline, the Cochrane Library of Medicine, Embase, and Health Business Elite found no existing systematic reviews of effectiveness evidence and economic evidence on intravenous iron administration on the correction of iron deficiency anaemia in the preoperative period.
Therefore this systematic review will aim to critically appraise, synthesise and present the best available evidence related to the effectiveness and economic cost-benefit ratio of intravenous iron administration on the correction of preoperative iron deficiency anaemia
Inclusion criteria
Types of participants
Both the quantitative component and the economic component of the review will consider studies that include adult patients presenting for major surgery, regardless of gender, ethnicity, diagnosis and comorbidities with pre-operative anaemia.
Types of intervention(s)/phenomena of interest
The quantitative component of the review will consider studies that evaluate the management of anaemia with iron infusions compared to oral iron treatment alone, oral iron in combination with erythropoietin, erythropoietin alone or haemoglobin correction with blood transfusion. This will include the dosage of iron, the frequency of its administration and the time frame of treatment prior to surgery. In addition it is of interest to assess how the intervention was employed, the personnel involved and the time spent to complete management.
The economic component of this review will consider studies that evaluate the costs and benefits (cost-effectiveness, cost-utility, or cost-benefit) of iron infusions compared to oral iron treatment or haemoglobin correction with blood transfusion for the treatment of pre-operative anaemia.
Types of outcomes
The quantitative component of this review will consider studies that include (but not limited to) the following outcome measures:
• The effect of iron administration on haemoglobin levels
• The rate of red blood cell (RBC) transfusion measured as proportion of patients transfused with allogeneic RBC and the average number of units transfused.
• The length of stay in hospital
• Rate of readmission within 30 days of discharge
• The incidence of transfusion related co-morbidities measured as infection rates, the occurrence of transfusion related lung injury (TRALI), transfusion related circulatory overload (TACO) and the number of deaths.
• The impact of intravenous iron administration on functional outcomes
The economic component of the review will consider (but not limited to) the following outcome measures:
• the reduction in costs for units of allogeneic blood avoided
• the reduction in cost associated with a reduction in length of stay in hospital LOS
• the reduction in transfusion laboratory cost and nursing time
• The increase in cost for iron administered and nursing time
Types of studies
The quantitative component of the review will consider any experimental study design including randomised controlled trials, non-randomised controlled trials, quasi-experimental, before and after studies for inclusion.
The economic component of the review will consider cost effectiveness, cost-utility, and cost-benefit studies for inclusion.
Search strategy
The search strategy aims to find both published and unpublished studies. A three-step search strategy will be utilised in this review. An initial limited search of MEDLINE will be undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe article. A second search using all identified keywords and index terms will then be undertaken across all included databases. Thirdly, the reference list of all identified reports and articles will be searched for additional studies. Studies published in English, German, Italian and Dutch will be considered for inclusion in this review. Awareness of transfusion and anaemia related outcomes have been addressed over the last 10 years. Therefore studies published from 2001 until December 2011 will be considered for inclusion in this review.
The databases to be searched included:
• PubMed
• EMBASE
• The Cochrane Library
• Health Business Elite database
• NHS Economic Evaluation Database (NHS EED) • Health Economic Evaluation Database (HEED)
The search for unpublished studies will include: MedNar and Proquest Dissertation and Thesis.
Initial keywords to be used will be: preoperative anaemia, iron deficiency, intravenous iron, oral iron, blood transfusion, adverse effects, cost-benefit, cost effectiveness, cost-utility.
Assessment of methodological quality
Quantitative papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardised critical appraisal instruments from the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBIMAStARI) (Appendix I). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.
Economic papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardised critical appraisal instruments from the Joanna Briggs Institute Analysis of Cost, Technology and Utilisation Assessment and Review Instrument (JBI-ACTUARI) (Appendix I). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.
Data collection
Quantitative data will be extracted from papers included in the review using the standardised data extraction tool from JBI-MAStARI (Appendix II). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives.
Economic data will be extracted from papers included in the review using the standardised data extraction tool from JBI-ACTUARI (Appendix II). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives.
Data synthesis
Quantitative papers will, where possible, be pooled in statistical meta-analysis using JBI-MAStARI. All results will be subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) and weighted mean differences (for continuous data) and their 95% confidence intervals will be calculated for analysis. Heterogeneity will be assessed statistically using the standard Chi-square. Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate. Economic findings will, where possible, be pooled using JBI-ACTUARI and presented in a tabular summary. Where this is not possible, findings will be presented in narrative form.
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